|Articles|April 1, 2004
Iron chelator CP94 enhances nodular BCC response to PDT
Washington - Enhanced 5-aminolevulinic acid photodynamic therapy (ALA PDT) performed with use of the novel iron chelator CP94 shows promise for improving the efficacy of topical PDT for nodular basal cell carcinoma (BCC), said Colin A. Morton, M.D., at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Phase 2 Nemolizumab Trial Opens for CPUO
5
